Cannabinoids

Journal of Pain and Symptom Management

Volumn 46, Issue 1, 2013, Pages 142-149

  Howard, Paul ^a   Twycross, Robert ^b   Shuster, John ^c   Mihalyo, Mary ^d   Wilcock, Andrew ^e  

^a Duchess of Kent House   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c VANDERBILT UNIVERSITY   (United States)

^d DUQUESNE UNIVERSITY   (United States)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRONABINOL; ENDOCANNABINOID; NABILONE; NABIXIMOLS; CANNABINOID;

ANOREXIA; CANCER PALLIATIVE THERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL PHARMACOLOGY; DRUG CONTRAINDICATION; DRUG FORMULATION; DRUG INDICATION; DRUG INFORMATION; DRUG INTERACTION; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PAIN; REFRACTORY PAIN; SHORT SURVEY; SPASTICITY; BRAIN; COMPLICATION; DRUG EFFECTS; METABOLISM; NAUSEA; NEOPLASM; DRUG EFFECT; REVIEW;

ANOREXIA; BRAIN; CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; NAUSEA; NEOPLASMS;

EID: 84892870283     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2013.05.002     Document Type: Short Survey

References (51)

1. Hill, A.J., Mercier, M.S., Hill, T.D., et al. Cannabidivarin is anticonvulsant in mouse and rat in vitro and in seizure models. Br J Pharmacol 167 (2012), 1629–1642.
2. Preet, A., Qamri, Z., Nasser, M.W., et al. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev Res (Phila) 4 (2011), 65–75.
3. Torres, S., Lorente, M., Rodríguez-Fornés, F., et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10 (2011), 90–103.
4. Tanasescu, R., Constantinescu, C.S., Cannabinoids and the immune system: an overview. Immunobiology 215 (2010), 588–597.
5. Stanley, C.P., Hind, W.H., O'Sullivan, S.E., Is the cardiovascular system a therapeutic target for cannabidiol?. Br J Clin Pharmacol 75 (2013), 313–322.
6. Scotter, E.L., Abood, M.E., Glass, M., The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 160 (2010), 480–498.
7. Castillo, P.E., Younts, T.J., Chávez, A.E., Hashimotodani, Y., Endocannabinoid signaling and synaptic function. Neuron 76 (2012), 70–81.
8. Beal, J.E., Olson, R., Laubenstein, L., et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10 (1995), 89–97.
9. Strasser, F., Luftner, D., Possinger, K., et al., Cannabis-In-Cachexia-Study-Group. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24 (2006), 3394–3400.
10. Jatoi, A., Windschitl, H.E., Loprinzi, C.L., et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20 (2002), 567–573.
11. Ahmedzai, S., Respiratory distress in the terminally ill patient. Respir Dis Pract 5 (1988), 21–29.
12. Pickering, E.E., Semple, S.J., Nazir, M.S., et al. Cannabinoid effects on ventilation and breathlessness: a pilot study of efficacy and safety. Chron Respir Dis 8 (2011), 109–118.
13. Izzo, A.A., Borrelli, F., Capasso, R., Di Marzo, V., Mechoulam, R., Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30 (2009), 515–527.
14. Wilkerson, J.L., Gentry, K.R., Dengler, E.C., et al. Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels. Pain 153 (2012), 1091–1106.
15. Gu, X., Mei, F., Liu, Y., et al. Intrathecal administration of the cannabinoid 2 receptor agonist JWH015 can attenuate cancer pain and decrease mRNA expression of the 2B subunit of N-methyl-D-aspartic acid. Anesth Analg 113 (2011), 405–411.
16. Yu, X.H., Cao, C.Q., Martino, G., et al. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain. Pain 151 (2010), 337–344.
17. Roques, B.P., Fournié-Zaluski, M.C., Wurm, M., Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat Rev Drug Discov 11 (2012), 292–310.
18. Huggins, J.P., Smart, T.S., Langman, S., Taylor, L., Young, T., An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153 (2012), 1837–1846.
19. Barnes, M.P., Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 7 (2006), 607–615.
20. Rea, K., Roche, M., Finn, D.P., Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. Br J Pharmacol 152 (2007), 633–648.
21. Mechoulam, R., Fride, E., Di Marzo, V., Endocannabinoids. Eur J Pharmacol 359 (1998), 1–18.
22. Pryce, G., Baker, D., Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 150 (2007), 519–525.
23. Tibirica, E., The multiple functions of the endocannabinoid system: a focus on the regulation of food intake. Diabetol Metab Syndr, 2, 2010, 5.
24. Pfitzer, T., Niederhoffer, N., Szabo, B., Central effects of the cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular regulation in anaesthetised rats. Br J Pharmacol 142 (2004), 943–952.
25. Calignano, A., Kátona, I., Désarnaud, F., et al. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 408 (2000), 96–101.
26. Atwood, B.K., Mackie, K., CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160 (2010), 467–479.
27. Gutierrez, T., Farthing, J.N., Zvonok, A.M., Makriyannis, A., Hohmann, A.G., Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 150 (2007), 153–163.
28. Scholz, J., Woolf, C.J., The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 10 (2007), 1361–1368.
29. Meng, I.D., Manning, B.H., Martin, W.J., Fields, H.L., An analgesia circuit activated by cannabinoids. Nature 395 (1998), 381–383.
30. Welch, S.P., Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry 21 (2009), 143–151.
31. Farquhar-Smith, W.P., Rice, A.S., Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology 94 (2001), 507–513 discussion 506A.
32. Hohmann, A.G., Herkenham, M., Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. Neurosci Lett 252 (1998), 13–16.
33. Brown, A.J., Novel cannabinoid receptors. Br J Pharmacol 152 (2007), 567–575.
34. Russo, E., Guy, G.W., A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66 (2006), 234–246.
35. Fusar-Poli, P., Crippa, J.A., Bhattacharyya, S., et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66 (2009), 95–105.
36. Wade, D.T., Robson, P., House, H., Makela, P., Aram, J., A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17 (2003), 21–29.
37. Notcutt, W., Price, M., Miller, R., et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 59 (2004), 440–452.
38. Johnson, J.R., Burnell-Nugent, M., Lossignol, D., et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39 (2010), 167–179.
39. Berman, J.S., Symonds, C., Birch, R., Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 112 (2004), 299–306.
40. Grotenhermen, F., Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42 (2003), 327–360.
41. Malone, D.T., Hill, M.N., Rubino, T., Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol 160 (2010), 511–522.
42. Simonetto, D.A., Oxentenko, A.S., Herman, M.L., Szostek, J.H., Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc 87 (2012), 114–119.
43. Davis, M.P., Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs 17 (2008), 85–95.
44. Lynch, M.E., Campbell, F., Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 72 (2011), 735–744.
45. Toth, C., Mawani, S., Brady, S., et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain 153 (2012), 2073–2082.
46. Langford, R.M., Mares, J., Novotna, A., et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 260 (2013), 984–997.
47. Wade, D.T., Makela, P.M., House, H., Bateman, C., Robson, P., Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 12 (2006), 639–645.
48. Nurmikko, T.J., Serpell, M.G., Hoggart, B., et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133 (2007), 210–220.
49. Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. http://dx.doi.org/10.1016/j.jpainsymman.2012.07.014.
50. Portenoy, R.K., Ganae-Motan, E.D., Allende, S., et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13 (2012), 438–449.
51. Canadian Agency for Drugs and Technologies in Health. Nabilone for chronic pain management: a review of clinical effectiveness, safety and guidelines. Rapid Response Report: summary with critical appraisal. 2011. Available from http://www.cadth.ca/media/pdf/htis/oct-2011/RC0306-000%20Nabilone%20for%20chronic%20pain.pdf. Accessed April 2013.